Concepedia

Author

C. Manegold

University Hospital Heidelberg

Also Known As

A. Märkel, C MANEGOLD, C Manegold, C h Manegold, C. MANEGOLD, C. Manegold, C.H. Manegold, Ch. Manegold, M Dietrich

142

Publications

3.6K

Citations

26

H-Index

50

Concepts

All Affiliations

University Hospital HeidelbergHeidelberg UniversityUniversity Medical Centre MannheimAsklepios Fachkliniken München-GautingLungenClinic Grosshansdorf
CM

About

C. Manegold is an author at University Hospital Heidelberg specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

18

28

2.3K

2

Health Sciences

9

9

1.4K

3

Engineering

1

1

122

4

Public Health

1

1

85

5

Epidemiology

1

1

85

C. Manegold

×

37

Publications

3.1K

Citations

22

H-Index

YearCitations

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Martin Reck, Joachim von Pawel, Petr Zatloukal,

Annals of Oncology

2010

640

Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency

Louis‐Daniel Brun, Lock Hock Ngu, Wee Teik Keng,

Neurology

2010

219

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

Fabio Efficace, Andrew Bottomley, Egbert F. Smit,

Annals of Oncology

2006

182

Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704

C. Manegold, Joachim von Pawel, Petr Zatloukal,

Journal of Clinical Oncology

2007

167

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

J M W van Haarst, Paul Baas, C. Manegold,

British Journal of Cancer

2002

158

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

C. Manegold, James T. Symanowski, U. Gatzemeier,

Annals of Oncology

2005

157

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial

C. Manegold, U. Gatzemeier, Joachim von Pawel,

Annals of Oncology

2000

155

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Giacomo Cartenì, C. Manegold, Germán Martín García,

Lung Cancer

2008

147

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

C. Manegold, Nico van Zandwijk, A. Szczęsna,

Annals of Oncology

2011

126

Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?

Gerald Schmid‐Bindert, Thomas Henzler, T. Q. Chu,

European Radiology

2011

122

Page 1